Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 2548 results for methods

  1. Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.

  2. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

  3. Bindex for investigating suspected osteoporosis (MIB106)

    NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .

  4. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  5. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.

  6. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  7. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  8. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

  9. Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)

    Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.

  10. Focal therapy using cryoablation for localised prostate cancer (IPG423)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

  11. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

  12. Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery (IPG121)

    Evidence-based recommendations on radiofrequency ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat to interrupt abnormal electrical signals.

  13. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.

  14. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

  15. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .